Biomarkers such as tumor mutational burden (TMB), PD-L1 expression, and tumor-infiltrating lymphocytes (TIL’s) have been previously investigated, however, none have been consistently validated or routinely adopted within clinical practice.21 Here, CD274 is linked to neoplasm.